Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
P/E ratio for Vincerx Pharma, Inc. (VINC)
P/E ratio as of 2023: -0.63
According to Vincerx Pharma, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.63. At the end of 2022 the company had a P/E ratio of -0.38.
P/E ratio history for Vincerx Pharma, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.63 |
| 2022 | -0.38 |
| 2021 | -11.21 |
| 2020 | -27.25 |
| 2019 | -1079.61 |